0	9	Decreased	decrease	VBN
10	23	concentration	concentration	NN
24	26	of	of	IN
27	48	1,25-dihydroxyvitamin	1,25-dihydroxyvitamin	NN
49	51	D3	d3	NN
52	61	receptors	receptor	NNS
62	64	in	in	IN
65	75	peripheral	peripheral	JJ
76	87	mononuclear	mononuclear	JJ
88	93	cells	cell	NNS
94	96	of	of	IN
97	105	patients	patient	NNS
106	110	with	with	IN
111	119	X-linked	x-linked	JJ
120	136	hypophosphatemic	hypophosphatemic	JJ
137	144	rickets	ricket	NNS
144	145	:	:	:
146	152	effect	effect	NN
153	155	of	of	IN
156	165	phosphate	phosphate	NN
166	181	supplementation	supplementation	NN
181	182	.	.	.

184	192	Abnormal	abnormal	JJ
193	198	renal	renal	JJ
199	206	tubular	tubular	JJ
207	216	phosphate	phosphate	NN
217	226	transport	transport	NN
227	229	is	be	VBZ
230	240	considered	consider	VBN
241	243	to	to	TO
244	246	be	be	VB
247	250	the	the	DT
251	258	primary	primary	JJ
259	265	defect	defect	NN
266	268	in	in	IN
269	277	X-linked	x-linked	JJ
278	294	hypophosphatemic	hypophosphatemic	JJ
295	302	rickets	ricket	NNS
303	304	(	(	(
304	307	XLH	XLH	NNP
307	308	)	)	)
308	309	.	.	.

310	317	However	however	RB
317	318	,	,	,
319	322	the	the	DT
323	333	resistance	resistance	NN
334	336	to	to	TO
337	344	vitamin	vitamin	NN
345	346	D	D	NNP
347	356	treatment	treatment	NN
357	359	in	in	IN
360	363	XLH	XLH	NNP
364	370	cannot	cannot	MD
371	373	be	be	VB
374	383	explained	explain	VBN
384	386	by	by	IN
387	403	hypophosphatemia	hypophosphatemia	NN
404	409	alone	alone	RB
409	410	.	.	.

411	416	Since	since	IN
417	421	most	most	JJS
422	424	of	of	IN
425	428	the	the	DT
429	436	actions	action	NNS
437	439	of	of	IN
440	447	vitamin	vitamin	NN
448	449	D	D	NNP
450	453	are	be	VBP
454	462	mediated	mediate	VBN
463	465	by	by	IN
466	469	its	its	PRP$
470	479	receptors	receptor	NNS
480	481	(	(	(
481	484	VDR	VDR	NNP
484	485	)	)	)
485	486	,	,	,
487	500	abnormalities	abnormality	NNS
501	503	of	of	IN
504	507	VDR	VDR	NNP
508	512	have	have	VBP
513	517	been	be	VBN
518	528	postulated	postulate	VBN
529	531	in	in	IN
532	535	XLH	XLH	NNP
535	536	.	.	.

537	539	In	in	IN
540	545	order	order	NN
546	548	to	to	TO
549	560	investigate	investigate	VB
561	565	this	this	DT
566	577	possibility	possibility	NN
577	578	,	,	,
579	581	we	we	PRP
582	590	measured	measure	VBD
591	594	the	the	DT
595	608	concentration	concentration	NN
609	611	of	of	IN
612	615	VDR	VDR	NNP
616	618	in	in	IN
619	632	PHA-activated	pha-activated	JJ
633	643	peripheral	peripheral	JJ
644	655	mononuclear	mononuclear	JJ
656	661	cells	cell	NNS
662	666	from	from	IN
667	669	10	10	CD
670	673	XLH	XLH	NNP
674	682	patients	patient	NNS
682	683	.	.	.

684	692	Patients	patient	NNS
693	700	without	without	IN
701	710	phosphate	phosphate	NN
711	726	supplementation	supplementation	NN
727	733	showed	show	VBD
734	747	significantly	significantly	RB
748	753	lower	low	JJR
754	767	concentration	concentration	NN
768	769	(	(	(
769	773	21.7	21.7	CD
774	777	+/-	+/-	SYM
778	781	5.1	5.1	CD
782	789	fmol/mg	fmol/mg	NN
790	797	protein	protein	NN
797	798	,	,	,
799	803	mean	mean	NN
804	807	+/-	+/-	SYM
808	811	SEM	sem	NN
811	812	)	)	)
813	821	compared	compare	VBN
822	824	to	to	TO
825	828	the	the	DT
829	835	normal	normal	JJ
836	844	controls	control	NNS
845	846	(	(	(
846	850	60.7	60.7	CD
851	854	+/-	+/-	CC
855	858	4.0	4.0	CD
858	859	)	)	)
859	860	.	.	.

861	863	On	on	IN
864	867	the	the	DT
868	876	contrary	contrary	NN
876	877	,	,	,
878	883	there	there	EX
884	887	was	be	VBD
888	890	no	no	DT
891	902	significant	significant	JJ
903	913	difference	difference	NN
914	921	between	between	IN
922	925	the	the	DT
926	948	phosphate-supplemented	phosphate-supplemented	JJ
949	957	patients	patient	NNS
958	959	(	(	(
959	963	58.3	58.3	CD
964	967	+/-	+/-	CC
968	971	2.7	2.7	CD
971	972	)	)	)
973	976	and	and	CC
977	985	controls	control	NNS
985	986	.	.	.

987	992	There	there	EX
993	996	was	be	VBD
997	998	a	a	DT
999	1010	significant	significant	JJ
1011	1019	positive	positive	JJ
1020	1031	correlation	correlation	NN
1032	1039	between	between	IN
1040	1043	VDR	VDR	NNP
1044	1057	concentration	concentration	NN
1058	1061	and	and	CC
1062	1067	serum	serum	NN
1068	1077	phosphate	phosphate	NN
1078	1079	(	(	(
1079	1080	P	p	NN
1081	1085	less	less	JJR
1086	1090	than	than	IN
1091	1095	0.05	0.05	CD
1095	1096	)	)	)
1096	1097	.	.	.

1098	1100	In	in	IN
1101	1104	two	two	CD
1105	1113	patients	patient	NNS
1113	1114	,	,	,
1115	1118	VDR	VDR	NNP
1119	1122	was	be	VBD
1123	1132	increased	increase	VBN
1133	1138	after	after	IN
1139	1144	daily	daily	JJ
1145	1154	phosphate	phosphate	NN
1155	1170	supplementation	supplementation	NN
1171	1174	was	be	VBD
1175	1182	started	start	VBN
1182	1183	.	.	.

1184	1189	These	these	DT
1190	1197	results	result	NNS
1198	1206	indicate	indicate	VBP
1207	1211	that	that	IN
1212	1213	a	a	DT
1214	1223	decreased	decrease	VBN
1224	1237	concentration	concentration	NN
1238	1240	of	of	IN
1241	1244	VDR	VDR	NNP
1245	1254	secondary	secondary	JJ
1255	1257	to	to	TO
1258	1268	persistent	persistent	JJ
1269	1285	hypophosphatemia	hypophosphatemia	NN
1286	1288	is	be	VBZ
1289	1292	one	one	CD
1293	1295	of	of	IN
1296	1299	the	the	DT
1300	1306	causes	cause	NNS
1307	1309	of	of	IN
1310	1317	vitamin	vitamin	NN
1318	1319	D	D	NNP
1320	1330	resistance	resistance	NN
1331	1333	in	in	IN
1334	1337	XLH	XLH	NNP
1337	1338	.	.	.